SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?


To: Marshall Teitelbaum who wrote (1769)3/16/1999 5:08:00 AM
From: jackie  Read Replies (1) | Respond to of 2205
 
To Marshall and all,

Has anyone commented on the Scientific American of April 1999? It has a major section on tissue engineering. Two articles discuss artificial skin developments. One by Nancy Parenteau of Organogenesis and the other by Gail Naughton of ATIS. Wonderful publicity for the technology and for both companies.

Regards,

Jack Simmons



To: Marshall Teitelbaum who wrote (1769)3/16/1999 3:43:00 PM
From: Rick Strange  Read Replies (2) | Respond to of 2205
 
Marshall,
Having attended several Security Analysis meetings, the extent of a favorable impression is related to how long they keep the free bar open. I wouldn't expect any new coverage until the stock gets above $5 since most analyst won't cover non-marginable stocks but maybe it will make the radar screen of a few.



To: Marshall Teitelbaum who wrote (1769)5/2/1999 5:28:00 PM
From: Bruce Long  Read Replies (2) | Respond to of 2205
 
Marshall,

I know that we have a partnership with S&N for Dermagraft, but do we currently have an agreement for ortho also. If not, could the wildcard be potentially Sulzer since they certainly have the money having just sold off their EP division for around $850 million.

Bruce Long